

BHIVA/BASHH guidelines on the use of pre-exposure prophylaxis: PICO questions and search strategy

PICO questions

Main

Population: All HIV-negative populations regardless of risk group and age.

Interventions: PrEP with antiretroviral therapy (incl maraviroc)

Comparators: Placebo, no-PrEP, TasP, PEP, condoms, biomedical and behavioural interventions

Outcomes: HIV infection, adverse events (e.g. toxicity or side effect, resistance, coercion), risk behaviours or risk compensation (includes condom use, number of sexual partners, STIs) and adherence, user acceptability, equity of access, cost effectiveness

Cost-effectiveness

Population: All HIV-negative populations regardless of risk group and age living in a high income country

Interventions: Oral PrEP with Truvada or tenofovir

Comparators: Placebo or no PrEP, TasP, PEP, condoms, behavioural interventions

Outcomes: HIV incidence/prevalence over time, total incremental cost, quality-adjusted life years gained or disability-adjusted life years averted, incremental cost-effectiveness ratio

Inclusion/exclusion criteria

RCT, non-RCT, cohort study evaluating the use of oral PrEP with antiretroviral therapy to prevent HIV infection

Measured one of the key outcomes: HIV infection, any adverse event, any stage III or IV adverse event, condom use, number of sexual partners, STIs and adherence, access

Published in a peer-review journal or presented as an abstract at a scientific conference between 15/10/2004 and 25/5/16.

Search strategy

Pharmacological search:

Limits: RCTs, SRs, Observational studies. English Language, Date: 2004-current

Economic search

Limits: Economic Filter

Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present

#	Searches	Results
1	exp HIV/	87060
2	exp HIV Infections/	244751
3	HIV Long-Term Survivors/	635
4	AIDS Serodiagnosis/	6268
5	(aids adj3 virus).ti,ab.	1966
6	(HIV or HIV1 or HIV2 or hiv-1 or hiv-2).ti,ab.	253092
7	(human immunodeficiency virus or human immunodeficiency virus or human immuno-deficiency virus or human immune-deficiency virus).ti,ab.	75096
8	(human immun\$ adj3 deficiency virus).ti,ab.	500

9	(acquired immunodeficiency syndrome or acquired immunodeficiency syndrome or acquired immunodeficiency syndrome or acquired immune-deficiency syndrome).ti,ab.	20302
10	(acquired immun\$ adj3 deficiency syndrome).ti,ab.	5400
11	or/1-10	341567
12	letter/	911571
13	editorial/	399615
14	news/	175882
15	exp historical article/	368008
16	Anecdotes as Topic/	4696
17	comment/	659992
18	case report/	1779433
19	(letter or comment*).ti.	109743
20	or/12-19	3629475
21	randomized controlled trial/ or random*.ti,ab.	931022
22	20 not 21	3609810
23	animals/ not humans/	4194782
24	exp Animals, Laboratory/	768520
25	exp Animal Experimentation/	7889
26	exp Models, Animal/	462506
27	exp Rodentia/	2861936
28	(rat or rats or mouse or mice).ti.	1187632
29	or/22-28	8428812
30	11 not 29	259261
31	exp Pre-Exposure Prophylaxis/	334
32	PrEP.ti,ab.	2325
33	((pre exposure* or pre-exposure*) adj2 (prophyla* or prevent*)).ti,ab.	861
34	exp Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination/	133
35	truvada.ti,ab.	106
36	exp Rilpivirine/	189
37	(rilpivirine or edurant).ti,ab.	334
38	dapivirine.ti,ab.	86
39	TMC10.ti,ab.	1
40	exp Tenofovir/	2648
41	(tenofovir or fumarate or TDF or vired).ti,ab.	10371
42	(maraviroc or selzentry or MVC).ti,ab.	4958
43	or/31-42	18601
44	30 and 43	4289
45	limit 44 to english language	4117
46	Meta-Analysis/	64499
47	Meta-Analysis as Topic/	14772
48	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.	90718
49	((systematic* or evidence*) adj2 (review* or overview*)).ti,ab.	104302
50	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.	30487
51	(search strategy or search criteria or systematic search or study selection or data extraction).ab.	33157
52	(search* adj4 literature).ab.	36908
53	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science	118294

	citation index or bids or cancerlit).ab.	
54	cochrane.jw.	12166
55	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.	1738
56	or/46-55	259129
57	Epidemiologic studies/	7091
58	exp Case control studies/	772656
59	exp Cohort studies/	1522887
60	Cross-sectional studies/	212368
61	case control.ti,ab.	92461
62	(cohort adj (study or studies or analys*)).ti,ab.	117919
63	((follow up or observational or uncontrolled or non randomi#ed or nonrandomi#ed or epidemiologic*) adj (study or studies)).ti,ab.	172651
64	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort*)).ti,ab.	942703
65	or/57-64	2276017
66	randomized controlled trial.pt.	413691
67	controlled clinical trial.pt.	90548
68	randomi#ed.ab.	410507
69	placebo.ab.	168840
70	drug therapy.fs.	1846114
71	randomly.ab.	247064
72	trial.ab.	355481
73	groups.ab.	1542363
74	or/66-73	3726751
75	clinical trials as topic.sh.	176165
76	trial.ti.	149327
77	or/66-69,71,75-76	1035685
78	56 or 65 or 77	3213043
79	45 and 78	1913
80	limit 79 to yr="2004 -Current" Results for Drugs search	1868
81	Economics/	26682
82	Value of life/	5492
83	exp "Costs and Cost Analysis"/	196640
84	exp Economics, Hospital/	21327
85	exp Economics, Medical/	13852
86	Economics, Nursing/	3933
87	Economics, Pharmaceutical/	2610
88	exp "Fees and Charges"/	28120
89	exp Budgets/	12788
90	budget*.ti,ab.	21707
91	cost*.ti.	92497
92	(economic* or pharmaco?economic*).ti.	37310
93	(price* or pricing*).ti,ab.	28722
94	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.	110428
95	(financ* or fee or fees).ti,ab.	87092
96	(value adj2 (money or monetary)).ti,ab.	1598

97	or/81-96	470334
98	45 and 97 Results for Economics search	182